Strategies to explore new approaches in the investigation and treatment of osteosarcoma

Cancer Treatment and Research

Volumn 152, Issue , 2009, Pages 517-528

  Kim, Su Young ^a   Helman, Lee J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA4 INTEGRIN; BIOLOGICAL MARKER; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; DEFOROLIMUS; EVEROLIMUS; EZRIN; INTEGRIN; MAMMALIAN TARGET OF RAPAMYCIN; PAXILLIN; PROTEIN P53; PROTEIN TYROSINE KINASE; RAPAMYCIN; RECQ HELICASE; RETINOBLASTOMA PROTEIN; SOMATOMEDIN; SOMATOMEDIN C; STROMAL CELL DERIVED FACTOR 1; TEMSIROLIMUS; CELL SURFACE RECEPTOR;

CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RESEARCH; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; FAMILIAL CANCER; FLUORESCENCE MICROSCOPY; GENE MUTATION; GENETIC ANALYSIS; GENETIC PREDISPOSITION; HIGH RISK PATIENT; HUMAN; LUNG METASTASIS; METASTASIS POTENTIAL; METHODOLOGY; NONHUMAN; ORTHOPEDIC SURGERY; OSTEOSARCOMA; OVERALL SURVIVAL; PATIENT CARE; PATIENT SELECTION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINOBLASTOMA; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; ANIMAL; BONE NEOPLASMS; CHROMOSOME ABERRATION; GENETICS; PATHOLOGY; PHYSIOLOGY; SECONDARY;

ANIMALS; BONE NEOPLASMS; CHROMOSOME ABERRATIONS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; OSTEOSARCOMA; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES;

EID: 77953676693     PISSN: 09273042     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-0284-9_31     Document Type: Conference Paper

References (34)

1. Dahlin DC, Coventry MB. Osteogenic sarcoma: a study of six hundred cases. J Bone Joint Surg Am. 1967;49A:101-110.
2. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol. 2002;20:776-790.
3. Meyers PA, Schwartz CL, Krailo M, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005;23:2004-2011.
4. Kempf-Bielack B, Bielack SS, Jurgens H, et al. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol. 2005;23:559-568.
5. Sandberg AA, Bridge JA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: osteosarcoma and related tumors. Cancer Genet Cytogenet. 2003;145:1-30.
6. Keith WN, Evans TRJ, Glasspool RM. Telomerase and cancer: time to move from a promising target to a clinical reality. J Pathol. 2001;195:404-414.
7. Savage SA, Stewart BJ, Liao JS, et al. Telomere stability genes are not mutated in osteosarcoma cell lines. Cancer Genet Cytogenet. 2005;160:79-81.
8. Ulaner GA, Huang HY, Otero J, et al. Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma. Cancer Res. 2003;63:1759-1763.
9. Sanders RP, Drissi R, Billups CA, et al. Telomerase expression predicts unfavorable outcome in osteosarcoma. J Clin Oncol. 2004;22:3790-3797.
10. Strahm B, Malkin D. Hereditary cancer predisposition in children: genetic basis and clinical implications. Int J Cancer. 2006;119:2001-2006.
11. Wadayama BI, Toguchida J, Shimizi T, et al. Mutation spectrum of the retinoblastoma gene in osteosarcomas. Cancer Res. 1994;54:3042-3048.
12. Feugeas O, Guriec N, Babin-Boilletot A, et al. Loss of heterozygosity in the RB gene is a poor prognostic factor in patients with osteosarcoma. J Clin Oncol. 1996;14:467-472.
13. Heinsohn S, Evermann U, Stadt UZ, et al. Determination of the prognostic value of loss of heterozygosity at the retinoblastoma gene in osteosarcoma. Int J Oncol. 2007;30:1205-1214.
14. Wunder JS, Gokgoz N, Parkes R, et al. TP53 mutations and outcome in osteosarcoma: a prospective, multicenter study. J Clin Oncol. 2005;23:1483-1490.
15. Wang LL. Biology of osteogenic sarcoma. Cancer J. 2005;11:294-305.
16. Nishijo K, Nakayama T, Aoyama T, et al. Mutation analysis of the RECQL4 gene in sporadic osteosarcomas. Int J Cancer. 2004;111:367-372.
17. Pollak M, Sem AW, Richard M, et al. Inhibition of metastatic behavior of murine osteosarcoma by hypophysectomy. J Natl Cancer Inst. 1992;84:966-971.
18. Pollak M, Polychronakos C, Richard M. Insulin like growth factor I: a potent mitogen for human osteogenic sarcoma. J Natl Cancer Inst. 1990;82:301-305.
19. Burrow S, Andrulis IL, Pollak M, et al. Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma. J Surg Oncol. 1998;69:21-27.
20. Mansky PJ, Liewehr DJ, Steinberg SM, et al. Treatment of metastatic osteosarcoma with the somatostatin analog OncoLar: significant reduction of Insulin-like Growth Factor-1 serum levels. J Pediatr Hematol Oncol. 2002;24:440-446.
21. Yeatman TJ. A renaissance for Src. Nat Rev Cancer. 2004;4:470-480.
22. Webb DJ, Donais K, Whitmore LA, et al. FAK-Src signalling through paxillin, ERK and MLCK regulates adhesion disassembly. Nat Cell Biol. 2004;6:154-161.
23. Azuma K, Tanaka M, Uekita T, et al. Tyrosine phosphorylation of paxillin affects the metastatic potential of human osteosarcoma. Oncogene. 2005;24:4754-4764.
24. Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer. 2002;2:91-100.
25. Khanna C, Wan X, Bose S, et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med. 2004;10:182-186.
26. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov. 2006;5:671-688.
27. Chawla SP, Sankhala KK, Chua V, et al. A phase II study of AP23573 (an mTOR inhibitor) in patients (pts) with advanced sarcomas. J Clin Oncol. 2005;23(suppl):9068.
28. Chawla SP, Tolcher AW, Staddon AP, et al. Updated results of a phase II trial of AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas. J Clin Oncol. 2006;24(suppl):9505.
29. Wan X, Mendoza A, Khanna C, Helman LJ. Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res. 2005;65:2406-2411.
30. Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410:50-56.
31. Laverdiere C, Hoang BH, Yang R, et al. Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma. Clin Cancer Res. 2005;11:2561-2567.
32. Perissinotto E, Cavalloni G, Leone F, et al. Involvement of chemokine receptor 4/stromal cell-derived factor 1 system during osteosarcoma tumor progression. Clin Cancer Res. 2005;11:490-497.
33. Kim SY, Lee CH, Midura BV, et al. Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases. Clin Exp Metastasis. 2008;25:201-211.
34. Bacci G, Briccoli A, Longhi A, et al. Treatment and outcome of recurrent osteosarcoma: experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy. Acta Oncol. 2005;44:748-755.